Pharma BD Deal Intelligence
Cinryze grew into a $450M+/year franchise that became ViroPharma's crown jewel, driving Shire's $4.2B buyout of the whole company six years later.
Full analysis, sources & comparables →Upfront consideration of $2.75 per share and potential total of $3.75 represent premiums of 49% and 103% over Lev's closing price. Lev Chairman Judson Cooper:…
ViroPharma agreed to buy Lev for $443M upfront plus up to $174M in CVRs tied to Cinryze regulatory and sales milestones; the deal diversifies ViroPharma ahead…
On October 21, 2008, we completed our acquisition of Lev Pharmaceuticals. As a result of the merger, we obtained Cinryze, a C1 inhibitor, approved by the FDA…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
$2.75/share upfront cash+stock + up to $1/share contingent; Cinryze hereditary angioedema
Cinryze grew into a $450M+/year franchise that became ViroPharma's crown jewel, driving Shire's $4.2B buyout of the whole company six years later.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| ViroPharma Incorporated / Lev Pharmaceuticals, Inc. (this deal) | 2008 | $443M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Alkermes plc / Cephalon, Inc. (Vivitrol rights) | 2008 | $27M | 83 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Fresenius SE / Fresenius Kabi / APP Pharmaceuticals, Inc. | 2008 | $3.7B | 67 |
← Browse all deals · How we score deals
More: 2008 deals